In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The drug is also intended for the treatment of glioblastoma multiforme
The segment delivered strong sales growth of 20% YoY
This is Enzene Biosciences third biosimilar to be approved
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
